ArticleCellular and molecular life sciences : CMLS2025
USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Regulatory roles of five key USP family deubiquitinases in cancer: from mechanisms to targeted therapy advances.Frontiers in pharmacology · 2026Review
- Adenosine signaling in tumor immune escape: metabolic checkpoints, myeloid suppression, and combination immunotherapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Deubiquitinating enzymes (DUBs) are crucial for regulating the degradation of specific proteins and represent a novel therapeutic direction in cancer. In gastric cancer, USP4 levels are significantly elevated, though its therapeutic potential remains underexplored. Our study demonstrates that USP4 plays a pivotal role in gastric cancer cells via the autophagy-dependent ferroptosis pathway. Specifically, USP4 selectively removes Lys48-linked polyubiquitin chains through its deubiquitination activity at the C311 site, stabilizing the A2AR protein. This action precisely modulates autophagy and inhibits ferroptosis, thereby promoting gastric cancer progression. Additionally, our findings indicate that targeting USP4 or A2AR can activate autophagy and restore the ferroptosis process, which is essential for autophagy-dependent ferroptosis. Consequently, the USP4-A2AR signaling pathway is critically important for the survival of gastric cancer cells and represents a potential therapeutic target for gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.